Evidence map›Paper›PMID 26566632›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2016

FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats.

X-M Qi, J Wang, X-X Xu, Y-Y Li, Y-G Wu

Open access · hybridAbstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Tacrolimus and diabetic rodent models.Pharmacological reports : PR · 2025
    Review
  5. Article
  6. Article
  7. Cytoskeleton Rearrangement in Podocytopathies: An Update.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Role of renal tubular programed cell death in diabetic kidney disease.Diabetes/metabolism research and reviews · 2023
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

X-M QiDepartment of Nephrology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
J WangDepartment of Nephrology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
X-X XuDepartment of Nephrology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Y-Y LiDepartment of Nephrology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Y-G WuDepartment of Nephrology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. wuyonggui@medmail.com.cn.
First Affiliated Hospital of Anhui Medical University · CNAnhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVE AND

designSeveral works in the setting of early experimental diabetic nephropathy using anti-inflammatory drugs, such as the calcineurin inhibitor FK506, have shown prevention of the development or amelioration of renal injury including proteinuria. The exact mechanisms by which anti-inflammatory drugs lower the albuminuria have not been still clarified well. MATERIALS: The diabetic rats were induced by using streptozotocin. TREATMENT: The diabetic rats were subjected to oral FK506 treatment at a dose of 0.5 or 1.0 mg/kg daily for 4 weeks.

methodsRenal histology for the ultrastructural evaluation was determined by electron microscope, followed by analyses of renal nephrin and podocin and detection of renal iNOS(+) macrophages and NF-κB-p-p65(+).

resultsElevated 24-h urinary albumin excretion rate was markedly attenuated by FK506 treatment. In diabetic model rats, FK506 treatment at a dose of 0.5 or 1.0 mg/kg significantly increased the expression of nephrin and podocin when compared to control. As expected, rats in control diabetic group had an increase in GBM thickening and foot process effacement when compared to normal rats; increased GBM thickening and foot process effacement were ameliorated by FK506 treatment with 0.5 and 1.0 mg/kg. Histologically, there was marked accumulation of ED-1(+)cells (macrophages) in diabetic kidneys, and FK506 treatment failed to inhibit it. In contrast, FK506 treatment at 0.5 and 1.0 mg/kg doses significantly inhibited the elevated ED-1(+)/iNOS(+) cells in the kidneys of diabetic rats. ED-1(+)/NF-κB-p-p65(+) cells were significantly increased in positive diabetic kidneys compared to those of normal rats. FK506 treatment at 0.5 and 1.0 mg/kg significantly attenuated the elevated ED-1(+)/NF-κB-p-p65(+) cells in diabetic kidneys. Additionally, a positive correlation was observed between ED-1(+)/iNOS(+) cells and albuminuria (r = 0.87, p < 0.05). Likewise, ED-1(+)/iNOS(+) cells were correlated negatively with both nephrin and podocin protein (r = -0.70, p < 0.05; r = -0.68, p < 0.05, respectively).

conclusionOur results show that FK506 not only upregulates expression of nephrin and podocin but also inhibits macrophage activation to protect against podocyte injury.

Indexed as

AlbuminuriaAnimalsBlood GlucoseCalcineurin InhibitorsDiabetes Mellitus, ExperimentalIntracellular Signaling Peptides and ProteinsKidneyMaleMembrane ProteinsMicroscopy, Electron, TransmissionRatsTacrolimusBlood GlucoseCalcineurin InhibitorsIntracellular Signaling Peptides and ProteinsMembrane ProteinsnephrinNPHS2 proteinTacrolimusDiabetic nephropathyFK506MacrophageNephrinPodocinPodocytes

Identifiers

PMID26566632
PMCPMC4712236
OpenAlexW2178958875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.